Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum.

Trial Profile

Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Alvocidib (Primary) ; Romidepsin (Primary)
  • Indications Cancer metastases; Lung cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 01 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top